These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
539 related articles for article (PubMed ID: 23741487)
1. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. Yang Y; Li H; Hou S; Hu B; Liu J; Wang J PLoS One; 2013; 8(5):e65309. PubMed ID: 23741487 [TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA AK126698 inhibits proliferation and migration of non-small cell lung cancer cells by targeting Frizzled-8 and suppressing Wnt/β-catenin signaling pathway. Fu X; Li H; Liu C; Hu B; Li T; Wang Y Onco Targets Ther; 2016; 9():3815-27. PubMed ID: 27445486 [TBL] [Abstract][Full Text] [Related]
3. LncRNA XIST acts as a MicroRNA-520 sponge to regulate the Cisplatin resistance in NSCLC cells by mediating BAX through CeRNA network. Liu TT; Li R; Liu X; Zhou XJ; Huo C; Li JP; Qu YQ Int J Med Sci; 2021; 18(2):419-431. PubMed ID: 33390811 [No Abstract] [Full Text] [Related]
4. Cisplatin and phenanthriplatin modulate long-noncoding RNA expression in A549 and IMR90 cells revealing regulation of microRNAs, Wnt/β-catenin and TGF-β signaling. Monroe JD; Moolani SA; Irihamye EN; Lett KE; Hebert MD; Gibert Y; Smith ME Sci Rep; 2021 May; 11(1):10408. PubMed ID: 34001990 [TBL] [Abstract][Full Text] [Related]
5. Microarray data re-annotation reveals specific lncRNAs and their potential functions in non-small cell lung cancer subtypes. Zhou D; Xie M; He B; Gao Y; Yu Q; He B; Chen Q Mol Med Rep; 2017 Oct; 16(4):5129-5136. PubMed ID: 28849055 [TBL] [Abstract][Full Text] [Related]
6. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway. Cai Y; Dong ZY; Wang JY Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323 [TBL] [Abstract][Full Text] [Related]
7. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway. Ma LY; Xie XW; Ma L; Pang JL; Xiong XM; Zheng HD; Shen XL; Wen ZG; Wang HY Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2626-2634. PubMed ID: 28678322 [TBL] [Abstract][Full Text] [Related]
8. LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway. Xu L; Xu Y; Yang M; Li J; Xu F; Chen BL BMC Pulm Med; 2020 Oct; 20(1):266. PubMed ID: 33059643 [TBL] [Abstract][Full Text] [Related]
9. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway. Jiang P; Xu H; Xu C; Chen A; Chen L; Zhou M; Haq IU; Wu X; Mariyam Z; Feng Q Chem Biol Interact; 2018 Dec; 296():154-161. PubMed ID: 30291867 [TBL] [Abstract][Full Text] [Related]
10. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway. Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493 [TBL] [Abstract][Full Text] [Related]
11. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway. Xia Y; He Z; Liu B; Wang P; Chen Y Mol Med Rep; 2015 Sep; 12(3):4530-4537. PubMed ID: 26059239 [TBL] [Abstract][Full Text] [Related]
12. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer. Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469 [TBL] [Abstract][Full Text] [Related]
13. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway. Gao BB; Wang SX Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077 [TBL] [Abstract][Full Text] [Related]
14. Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma. Hu L; Chen J; Zhang F; Wang J; Pan J; Chen J; Wang Y Biomed Res Int; 2017; 2017():7498151. PubMed ID: 29279851 [TBL] [Abstract][Full Text] [Related]
15. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis. Wang L; Shang X; Feng Q Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109 [TBL] [Abstract][Full Text] [Related]
16. Silence of fibronectin 1 increases cisplatin sensitivity of non-small cell lung cancer cell line. Gao W; Liu Y; Qin R; Liu D; Feng Q Biochem Biophys Res Commun; 2016 Jul; 476(1):35-41. PubMed ID: 27207836 [TBL] [Abstract][Full Text] [Related]
17. Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer. Cheng N; Li X; Zhao C; Ren S; Chen X; Cai W; Zhao M; Zhang Y; Li J; Wang Q; Zhou C Oncol Rep; 2015 Feb; 33(2):833-9. PubMed ID: 25482516 [TBL] [Abstract][Full Text] [Related]
18. Knockdown of lncRNA-XIST enhances the chemosensitivity of NSCLC cells via suppression of autophagy. Sun W; Zu Y; Fu X; Deng Y Oncol Rep; 2017 Dec; 38(6):3347-3354. PubMed ID: 29130102 [TBL] [Abstract][Full Text] [Related]
19. LncRNA PCIF1 promotes aerobic glycolysis in A549/DDP cells by competitively binding miR-326 to regulate PKM expression. Zhong W; Wang C; Sun Y Mol Cell Probes; 2024 Oct; 77():101977. PubMed ID: 39074568 [TBL] [Abstract][Full Text] [Related]
20. LncRNA XIST promotes human lung adenocarcinoma cells to cisplatin resistance via let-7i/BAG-1 axis. Sun J; Pan LM; Chen LB; Wang Y Cell Cycle; 2017; 16(21):2100-2107. PubMed ID: 28961027 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]